Therma Bright Inc. News Releases

Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually

Tue, 31 Mar 2026 06:30:00 -0400

Therma Bright Builds on Revenue Progress with Initial 100-Unit Venowave™ Order; Signals Expansion into Cosmetic Wellness MarketToronto, Ontario--(Newsfile Corp. - March 31, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces it has secured a strategic commercial order for an initial 100 Venowave™ units from Horizon Health ("Horizon").This...

Therma Bright Grants Stock Options

Fri, 13 Mar 2026 17:54:00 -0400

Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces that it has granted incentive stock options to its directors, officers and certain consultants of the Company to purchase up to an aggregate of 2,850,000 common shares of the Company pursuant to its 10% rolling stock option plan. All options...

Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial

Tue, 10 Feb 2026 07:00:00 -0500

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a major clinical milestone for its portfolio company, Inretio. The medical device innovator has successfully completed the first cohort of the First-in-Human (FIH) study for the PREVA™ Neuro-Thrombectomy System, moving the...

Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med

Tue, 20 Jan 2026 06:30:00 -0500

Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce it has received a follow-on order for an additional 200 Venowave™ VW5 units from its Texas-based distribution partner, Gen-X Med. This latest transaction marks the expansion of the relationship between the two companies,...

Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.

Thu, 18 Dec 2025 07:00:00 -0500

Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025 Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on Investee company, InStatin.InStatin, a biotechnology company developing inhaled statin therapies for respiratory diseases, today reported...

Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors

Fri, 10 Oct 2025 06:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 10, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the appointment of Michael Raimondo, a 30-year veteran in sales and operations in the healthcare industry to its Board of Directors. Michael was part of Therma's advisory Board, previously announced on August 13, 2024.Mr. Raimondo is a...

Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales

Wed, 24 Sep 2025 06:30:00 -0400

Initial 200-Unit Sale previously announced on April 24, 2025, Targeted Specialized Knee Surgeons in U.S. Healthcare Network Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a strategic partnership with Gen-X Med, a specialized medical product distributor based in...

Therma Bright Proposes to Amend Certain Warrants

Thu, 28 Aug 2025 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 28, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company") announces that subject to the approval of the TSX Venture Exchange (the "TSXV"), the Company intends to amend the exercise price of an aggregate of 6,250,000 outstanding post-consolidation common share purchase warrants of the Company (the "Warrants") that were issued as part of the Company's private placement ("Private Placement") that closed in...

Therma Bright Announces Share Consolidation

Thu, 03 Jul 2025 06:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 3, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company") announces, further to its news release dated June 11, 2025, that effective Tuesday, July 8, 2025, the Company will consolidate the common shares in the capital of the Company (the "Shares") on the basis of one (1) post-consolidation Share for every eight (8) pre-consolidation Shares (the "Consolidation"). The new CUSIP number will be 883426207 and the...

Therma Bright Inc. Announces Share Consolidation

Wed, 11 Jun 2025 06:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces, subject to the approval of the TSX Venture Exchange (the "TSXV"), that it will be undertaking a consolidation (the "Consolidation") of its common shares on the basis of eight (8) pre-Consolidation common shares for one (1)...